Real-world study data on Leqembi treatment presented
Real-world LEADER study data shows over 75% of patients with early Alzheimer's disease remained stable or improved on Leqembi treatment over an average of 17 months.
BioArctic AB's partner Eisai presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study at the Alzheimer's Association International Conference® (AAIC®) 2026.
The study found that nearly 83% of patients with early Alzheimer's disease remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. These findings were consistent across sex, race, ethnicity, and APOE genotype, supporting the long-term benefits of continuous treatment.
The LEADER study is a retrospective, multicenter real-world study that gathered data from 13 U.S. clinical sites to examine Leqembi utilization, treatment persistence, safety, and cognitive and functional assessments in a clinical setting. The interim analysis included 432 patients with early Alzheimer's disease.
Of the 432 participants, 75.9% remained in the same disease stage, and 6.6% improved from mild dementia to mild cognitive impairment (MCI). Nearly 87% of patients chose to remain on Leqembi treatment.
The study's safety observations were consistent with the U.S. FDA-approved label. ARIA (amyloid-related imaging abnormalities) was observed in 12.3% of patients, with most cases being asymptomatic or mild.